Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Enterprise Value: 2020-2025

Historic Enterprise Value for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $1.2 billion.

  • Xeris Biopharma Holdings' Enterprise Value rose 244.23% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 776.79%. This contributed to the annual value of $433.8 million for FY2024, which is 72.03% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Enterprise Value stood at $1.2 billion for Q3 2025, which was up 77.58% from $688.6 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Enterprise Value peaked at $1.2 billion during Q3 2025, and registered a low of $58.9 million during Q4 2022.
  • In the last 3 years, Xeris Biopharma Holdings' Enterprise Value had a median value of $279.1 million in 2023 and averaged $437.9 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Enterprise Value crashed by 77.60% in 2022 and then soared by 328.13% in 2023.
  • Over the past 5 years, Xeris Biopharma Holdings' Enterprise Value (Quarterly) stood at $263.0 million in 2021, then crashed by 77.60% to $58.9 million in 2022, then surged by 328.13% to $252.1 million in 2023, then surged by 72.03% to $433.8 million in 2024, then soared by 244.23% to $1.2 billion in 2025.
  • Its Enterprise Value was $1.2 billion in Q3 2025, compared to $688.6 million in Q2 2025 and $786.7 million in Q1 2025.